Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Abeona Therapeutics Inc (ABEO) vs Baxter International Inc (BAX) Price & Performance

Abeona Therapeutics IncTrade
Baxter International IncTrade

Price performance (Past 24H)

Key statistics

Abeona Therapeutics Inc vs Baxter International Inc — how do they compare? Abeona Therapeutics Inc trades at $7.57 (market cap $421.19M), while Baxter International Inc trades at $27.56 (market cap $14.27B). The key difference: Baxter International Inc is far larger — about 33.9× Abeona Therapeutics Inc's market cap, and Baxter International Inc pays a 0.14% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.

ABEOBAX
Market Cap
$421.19M$14.27B
Sector
HealthHealth
52-Week High
$7.45$28.35
52-Week Low
$4.17$15.80
Enterprise Value
$276.10M$21.79B
Dividend Yield
0.14%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Abeona Therapeutics Inc

No Aura AI signal available yet.

Baxter International Inc

Baxter International Inc. (BAX) trades at $27.78, up 0.83% today, with a bullish technical outlook supported by moving averages. Recent Q2 2026 earnings beat estimates with EPS of $0.56 versus $0.37 expected, and revenue guidance was raised, signaling operational improvement. However, the company posted a net loss of -$957 million in 2025, with negative profit margins and high P/E of 87.85, reflecting valuation concerns amid turnaround efforts.

The stock shows potential from earnings momentum and cost initiatives, but high debt and inconsistent profitability pose risks. Analyst consensus is mixed with a $25.43 price target below current levels, suggesting cautious optimism. Investors should weigh recent beats against structural challenges in the medtech sector.

Returns comparison

Trailing returns across standard periods

About Abeona Therapeutics Inc

Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.

Read more on ABEO

About Baxter International Inc

Baxter offers a variety of medical instruments and supplies to caregivers. It enhanced its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021. Legacy Baxter offers tools to help patients with acute and chronic kidney failure. It also sells a variety of injectable therapies for use in care settings, such as IV pumps, and administrative sets.

Read more on BAX